• Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2023 on September 28

    المصدر: Nasdaq GlobeNewswire / 25 سبتمبر 2023 07:00:40   America/New_York

    LONDON and SALT LAKE CITY, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) will report its fourth quarter and full year fiscal 2023 financial results on Thursday, September 28, 2023, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (BST).

    Conference Call Details:
    To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided in order for interested parties to join the conference call.

    Webcast Registration link: https://edge.media-server.com/mmc/p/bmrco2si

    For further information, please contact:

    Renalytix plc www.renalytix.com
    James McCullough, CEOVia Walbrook PR
      
    Stifel (Nominated Adviser, Joint Broker)Tel: 020 7710 7600
    Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea 
      
    Investec Bank plc (Joint Broker)Tel: 020 7597 4000
    Gary Clarence / Shalin Bhamra 
      
    Walbrook PR LimitedTel: 020 7933 8780 or renalytix@walbrookpr.com
    Paul McManus / Lianne ApplegarthMob: 07980 541 893 / 07584 391 303
      
    CapComm Partners 
    Peter DeNardo

    		Tel: 415-389-6400 or investors@renalytix.com

    About Renalytix
    Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.


    Primary Logo

شارك على،